Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03424-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2026. Verfasst von Zijie Nie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Diseases. Die Arbeit nennt 183 Literaturangaben. Gefördert von: Shanghai Rising-Star Program.
Abstract (Originalsprache)
Prostate cancer (PCa) remains one of the most prevalent malignancies and a major cause of cancer-related deaths among men worldwide. Current pre-biopsy evaluation relies primarily on serum prostate-specific antigen (PSA) testing and multiparametric MRI (mpMRI), but both approaches have limited specificity, particularly in the diagnostic gray zone (PSA 4-10 ng/mL and/or equivocal MRI findings such as Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions). In this setting, overlap between PCa and benign prostatic diseases frequently leads to unnecessary biopsies. This unmet clinical need has driven the development of novel diagnostic strategies designed to better discriminate PCa from benign prostatic diseases before biopsy. In this review, we provide a comprehensive overview of recent advances in non-invasive diagnostic strategies, including liquid-based molecular biomarkers, advanced imaging modalities, and multimodal integrative frameworks. These advances may improve diagnostic accuracy, reduce unnecessary biopsies, and support personalized risk stratification and biopsy decision-making. Moreover, we highlight the paradigm shift from single-parameter screening to multimodal integration, including artificial intelligence-based approaches in early PCa screening. Overall, these non-invasive strategies may help reduce diagnostic uncertainty in the gray zone and support more precise and personalized biopsy decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Dongfang Road No.1630, 20012…
Förderung
- Shanghai Rising-Star Program
Zitieren
APA
Nie, Z., Zhu, T., Chen, Y., Zhang, W., & Wu, L. (2026). Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population. Medical Oncology. https://doi.org/10.1007/s12032-026-03424-1
Vancouver
Nie Z, Zhu T, Chen Y, Zhang W, Wu L. Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population. Medical Oncology. 2026. doi:10.1007/s12032-026-03424-1
BibTeX
@article{Nie2026,
author = {Nie, Zijie and Zhu, Tianyi and Chen, Yichu and Zhang, Wei and Wu, Lingling},
title = {Recent advances in discriminating prostate cancer from benign prostatic diseases in the pre-biopsy population},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03424-1}
}
EUVIMED